SCHEMBL4124716

SCHEMBL4124716

CCc1ccc(NC(=O)Nc2ccc(C)cc2F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.56
NPC1 O15118 7/20 0.56
SMN1; SMN2 Q16637 7/20 0.56
MAPT P10636 5/20 0.56
PKM P14618 2/20 0.56
POLB P06746 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LMNA P02545 2/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
TP53 P04637 1/20 0.51
HTT P42858 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
ALDH1A1 P00352 1/20 0.49
SAE1 Q9UBE0 1/20 0.49
UBA2 Q9UBT2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4106038 0.89 RAB9A (0.70) RAB9ANPC1SMN1; SMN2MAPTPKM
SCHEMBL4124525 0.86 NTRK1 (0.55) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL4106843 0.83 RAB9A (0.56) RAB9ANPC1SMN1; SMN2MAPTPKM
SCHEMBL4112512 0.82 RAB9A (0.69) RAB9ANPC1SMN1; SMN2MAPTPOLB
SCHEMBL16942605 0.81 RAB9A (0.53) RAB9ANPC1SMN1; SMN2MAPTPKM
SCHEMBL16946643 0.80 MAPT (0.76) RAB9ANPC1SMN1; SMN2MAPTPOLB
SCHEMBL18377753 0.78 CA2 (0.76) MAPTMEN1KMT2ACA12CA1
SCHEMBL4127751 0.78 RAB9A (0.56) RAB9ANPC1SMN1; SMN2MAPTPKM
SCHEMBL4116098 0.78 RAB9A (0.57) RAB9ANPC1SMN1; SMN2MAPTPOLB
SCHEMBL4113855 0.78 RAB9A (0.79) RAB9ANPC1SMN1; SMN2MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 RAB9A 815/4885NPC1 927/4885SMN1; SMN2 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.